Positive Quality Intervention: Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

**Description:** Sotorasib (Lumakras®) is a first-in-class oral medication FDA-approved for the treatment of adult patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. In order to be assessed for drug eligibility, a patient’s KRAS G12C positive status must first be determined by an FDA-approved companion diagnostics test including QIAGEN therascreen® KRAS RGQ PCR Kit or Guardant360® CDx prior to therapy initiation.\(^1\)\(^2\)

**Background:** Sotorasib is the first FDA-approved, once-daily, oral, highly selective KRAS inhibitor proven to successfully target KRAS G12C, a once deemed undruggable target. The KRAS protein functions as an on/off switch to the body’s cell growth regulator. When the KRAS protein becomes mutated, the cellular on/off switch becomes fixed in the “on” position thereby leading to tumor formation caused by continuous and uncontrollable cell growth. KRAS G12C is documented as one of the most common oncogenic driver mutations seen in NSCLC, whereby 1 in 8 NSCLC patients possess this biomarker.\(^3\) KRAS mutations are most often found in smokers; however they can occur regardless of clinical or demographic characteristics.\(^2\) Proven to have reduced responsiveness to EGFR tyrosine kinase inhibitors, this actionable driver mutation now highlights a gene-drug match with sotorasib (Lumakras®) as a targeted treatment option for eligible patients.\(^4\) Such personalized treatment regimens are planned and tailored with the clinical application of pharmacogenomic test results from FDA-approved tissue and/or liquid companion diagnostics utilizing Next Generation Sequencing (NGS), real-time polymerase chain reaction (PCR), and Sanger sequencing methods. KRAS G12C testing via a comprehensive broad molecular panel or single-gene biomarker testing should be considered for all NSCLC at diagnosis as this mutation is considered to be truncal (clonal) in nature - typically arising early on and remaining stable during disease progression.\(^2\)

**PQI Process:**
- Upon consideration of treatment with sotorasib (Lumakras®), ensure KRAS G12C-mutation and patient has received at least one prior systemic therapy
  - Clinical practice guidelines including NCCN, ASCO, and CAP/IASLC/AMP recommend testing for actionable biomarkers such as KRAS in all eligible patients with advanced NSCLC utilizing either a comprehensive panel or targeted testing\(^2\)
  - The NCCN Guidelines for NSCLC provide recommendations for individual biomarkers that should be tested and testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories\(^4\)
- Companion Diagnostics Test Selection
  - FDA-approved tissue and liquid companion diagnostics are available to test for KRAS G12C using well-validated common molecular testing methods\(^2\)
  - Physicians should use their own medical judgment in determining which test is most appropriate for their patients
  - Treatment is indicated based on the presence of the KRAS G12C mutation in either tumor or plasma/liquid biopsy specimens. Liquid biopsy has high degrees of concordance with tissue-based testing, with 93% concordance for KRAS mutations in patients with mNSCLC.\(^2\) However, if no mutation is detected in a plasma specimen, tumor tissue should be tested for confirmation.
  - Tissue PCR: QIAGEN therascreen® KRAS RGQ PCR Kit\(^5,6\)
    - First and only FDA-approved tissue diagnostic for KRAS G12C to help guide the

**IMPORTANT NOTICE:** NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. Updated 11.29.23
treatment of NSCLC

- Detection of 7 somatic mutations in KRAS gene (codons 12/13 including KRAS G12C)
- Available as a ready-to-use kit and reagents
  - Liquid NGS: Guardant360 ® CDx
    - The first FDA-approved liquid biopsy test that utilizes NGS
    - Designed to detect 55 gene mutations found in circulating cell-free DNA (cfDNA) within the patient’s blood
    - A liquid biopsy is useful to replace or complement tissue analysis, depending on the clinical scenario (ex. if the patient is unable to repeat a tissue biopsy or if there is insufficient tissue sample remaining from their original tissue biopsy to allow for testing)

- Clinical Practice Recommendations:
  - Information on the aforementioned FDA-approved companion diagnostics tests can be found at www.qiagen.com/KRAS and www.guardant360cdx.com
  - Assess a patient’s archival tissue to determine its eligibility based on limited quantity or deemed insufficient for NGS
  - When comparing broad molecular profiling versus single-gene biomarker testing, it has been noted that comprehensive panel testing conserves tissue and is cost-effective while avoiding the added cost and risk of a repeat biopsy
  - KRAS mutations are reported at the variant level, thus the provider should be aware of the various nomenclatures for interpretation by which the specific variant may be notated (ex. KRAS G12C, KRAS Gly12Cys or KRAS 12Cys)
  - For eligible patients, retrospective data mining is recommended for past reports of KRAS G12C identified as a variant of unknown/uncertain significance (VUS) prior to the approval of sotorasib (Lumakras®)
  - Consider formulating a plan to maintain records of test results for all actionable biomarkers for future reference

Patient-Centered Activities:

- Testing for actionable biomarkers is recommended at diagnosis via a broad, panel-based approach
- All eligible patients with NSCLC should consider seeking testing for KRAS G12C
- KRAS G12C testing can be performed via a biopsy either using tissue from the tumor (tissue biopsy) or a blood test (liquid biopsy)
- Patients are encouraged to share any prior pathology, germline (genetic testing), and/or somatic (NGS, PCR, etc.) reports with their current healthcare team in order to provide full access to the patient’s identified predictive and prognostic biomarkers for the best informed treatment decisions based on precision medicine
- A patient’s out-of-pocket (OOP) cost will vary depending on their insurance; the average patient OOP cost is $0 for original Medicare and $65 for commercially insured patients
  - Financial assistance is also offered through many of the commercially available biomarker assays or laboratories

References:
2. Lumakras® (sotorasib) [KRAS G12C testing information], Thousand Oaks, CA: Amgen, Inc.
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v.5.2022.
5. QIAGEN therascreen® KRAS RGQ PCR Kit CDx test Flashcard.
7. Guardant360® CDx test Flashcard.